Skip to main content
Erschienen in: Cancer Causes & Control 11/2010

01.11.2010 | Original paper

Factors associated with Type I and Type II endometrial cancer

verfasst von: Ashley S. Felix, Joel L. Weissfeld, Roslyn A. Stone, Robert Bowser, Mamatha Chivukula, Robert P. Edwards, Faina Linkov

Erschienen in: Cancer Causes & Control | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

We investigated risk factors for Type II (n = 176) vs. Type I (n = 1,576) endometrial cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008.

Methods

Clinical data were available from the University of Pittsburgh Medical Center (UPMC) Network Cancer Registry. Logistic regression was used to estimate the adjusted odds of having Type II EC vs. Type I EC. Risk factors of interest in this analysis were age, race, body mass index (BMI), year of diagnosis, parity, menopausal status, and history of additional primary tumors.

Results

Relative to women with Type I EC, women with Type II EC were more likely to be older at diagnosis (OR: 1.03 per 1 year increase in age, 95% CI 1.01–1.05), of non-white race (OR: 2.95, 95% CI 1.66–5.27), have a history of additional primary tumors (OR: 1.56, 95% CI 1.05–2.32), and less likely to be obese (OR: 0.45, 95% CI 0.29–0.70).

Conclusion

In this large retrospective cohort of patients with EC, the striking difference in risk factors associated with Type II vs. Type I tumors suggests that these subtypes represent different disease entities that require different treatment modalities. Currently, Type II cases have a significantly worse prognosis compared to Type I. Further characterization of risk factors associated with developing Type II tumors is needed to prevent this aggressive malignancy.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249CrossRefPubMed
2.
Zurück zum Zitat Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH (2007) Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol 62(1):28–34 discussion 5–6CrossRefPubMed Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH (2007) Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol 62(1):28–34 discussion 5–6CrossRefPubMed
3.
Zurück zum Zitat Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111(2 Pt 1):436–447PubMed Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111(2 Pt 1):436–447PubMed
4.
Zurück zum Zitat Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A et al (2008) Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198(2):218 e1-e6CrossRefPubMed Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A et al (2008) Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198(2):218 e1-e6CrossRefPubMed
5.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130CrossRefPubMed Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130CrossRefPubMed
6.
Zurück zum Zitat Adami HO (ed) (2008) Textbook of cancer epidemiology. Oxford University Press Inc, New York Adami HO (ed) (2008) Textbook of cancer epidemiology. Oxford University Press Inc, New York
7.
Zurück zum Zitat Lauchlan SC (1981) Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 105(11):615–618PubMed Lauchlan SC (1981) Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 105(11):615–618PubMed
8.
Zurück zum Zitat Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6(2):93–108CrossRefPubMed Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6(2):93–108CrossRefPubMed
9.
Zurück zum Zitat Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17CrossRefPubMed Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17CrossRefPubMed
10.
Zurück zum Zitat Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S et al (2008) Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 108(3–5):221–229CrossRefPubMed Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S et al (2008) Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 108(3–5):221–229CrossRefPubMed
11.
Zurück zum Zitat Ryan AJ, Susil B, Jobling TW, Oehler MK (2005) Endometrial cancer. Cell Tissue Res 322(1):53–61CrossRefPubMed Ryan AJ, Susil B, Jobling TW, Oehler MK (2005) Endometrial cancer. Cell Tissue Res 322(1):53–61CrossRefPubMed
12.
Zurück zum Zitat Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS (2008) Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 168(6):563–570 discussion 71–76CrossRefPubMed Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS (2008) Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 168(6):563–570 discussion 71–76CrossRefPubMed
13.
Zurück zum Zitat Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ (2007) Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 26(2):103–114CrossRefPubMed Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ (2007) Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 26(2):103–114CrossRefPubMed
14.
Zurück zum Zitat Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB et al (2008) Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 113(8):2073–2081CrossRefPubMed Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB et al (2008) Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 113(8):2073–2081CrossRefPubMed
15.
Zurück zum Zitat Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11(12):1531–1543PubMed Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11(12):1531–1543PubMed
16.
Zurück zum Zitat Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4):814–824CrossRefPubMed Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4):814–824CrossRefPubMed
17.
Zurück zum Zitat Yi X, Zheng W (2008) Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol 20(1):20–25CrossRefPubMed Yi X, Zheng W (2008) Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol 20(1):20–25CrossRefPubMed
18.
Zurück zum Zitat Dunton CJ, Balsara G, McFarland M, Hernandez E (1991) Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv 46(2):97–102CrossRefPubMed Dunton CJ, Balsara G, McFarland M, Hernandez E (1991) Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv 46(2):97–102CrossRefPubMed
19.
Zurück zum Zitat Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O’Malley DM et al (2009) An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 115(2):244–248CrossRefPubMed Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O’Malley DM et al (2009) An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 115(2):244–248CrossRefPubMed
20.
Zurück zum Zitat Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA et al (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5):642–646PubMed Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA et al (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5):642–646PubMed
21.
Zurück zum Zitat Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS et al (1999) Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74(3):385–394CrossRefPubMed Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS et al (1999) Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74(3):385–394CrossRefPubMed
22.
Zurück zum Zitat Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C et al (2008) Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol 29(1):57–60PubMed Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C et al (2008) Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol 29(1):57–60PubMed
23.
Zurück zum Zitat Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gitsch G, Gilbert L (2007) Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. Anticancer Res 27(2):1213–1217PubMed Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gitsch G, Gilbert L (2007) Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. Anticancer Res 27(2):1213–1217PubMed
24.
Zurück zum Zitat Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB (2009) Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 115(1):142–153CrossRefPubMed Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB (2009) Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 115(1):142–153CrossRefPubMed
25.
Zurück zum Zitat Mendivil A, Schuler KM, Gehrig PA (2009) Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 16(1):46–52PubMed Mendivil A, Schuler KM, Gehrig PA (2009) Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 16(1):46–52PubMed
27.
Zurück zum Zitat Linkov F, Taioli E (2008) Factors influencing endometrial cancer mortality: the Western Pennsylvania Registry. Future Oncol 4(6):857–865CrossRefPubMed Linkov F, Taioli E (2008) Factors influencing endometrial cancer mortality: the Western Pennsylvania Registry. Future Oncol 4(6):857–865CrossRefPubMed
28.
Zurück zum Zitat Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26(11):1268–1274CrossRefPubMed Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26(11):1268–1274CrossRefPubMed
30.
Zurück zum Zitat Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR et al (2007) Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31(7):979–987CrossRefPubMed Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR et al (2007) Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31(7):979–987CrossRefPubMed
31.
Zurück zum Zitat Bjorge T, Engeland A, Tretli S, Weiderpass E (2007) Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 120(2):378–383CrossRefPubMed Bjorge T, Engeland A, Tretli S, Weiderpass E (2007) Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 120(2):378–383CrossRefPubMed
32.
Zurück zum Zitat Boruta DM 2nd, Gehrig PA, Groben PA, Bae-Jump V, Boggess JF, Fowler WC Jr et al (2004) Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 101(10):2214–2221CrossRefPubMed Boruta DM 2nd, Gehrig PA, Groben PA, Bae-Jump V, Boggess JF, Fowler WC Jr et al (2004) Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 101(10):2214–2221CrossRefPubMed
33.
Zurück zum Zitat Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS et al (2000) The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77(1):55–65CrossRefPubMed Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS et al (2000) The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77(1):55–65CrossRefPubMed
Metadaten
Titel
Factors associated with Type I and Type II endometrial cancer
verfasst von
Ashley S. Felix
Joel L. Weissfeld
Roslyn A. Stone
Robert Bowser
Mamatha Chivukula
Robert P. Edwards
Faina Linkov
Publikationsdatum
01.11.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 11/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9612-8

Weitere Artikel der Ausgabe 11/2010

Cancer Causes & Control 11/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.